While the recent litigation settlement provides a five-year protection for Exparel, the threat of generic competition looms on the horizon. Once this protection expires, Pacira may face significant challenges in maintaining its market share. Generic alternatives could lead to price pressures and potentially erode Exparel's dominant position in the non-opioid pain management market.